• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Xencor Inc.

    4/27/26 4:03:39 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    DEFA14A 1 xencorincdefa14a-2026.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material under §240.14a-12
    XENCOR, INC.
    (Name of Registrant as Specified in its Charter)
    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required
    oFee paid previously with preliminary materials
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11




    xencorincregnoticev3_pagex1a.jpg



    xencorincregnoticev3_pagex2a.jpg

    Get the next $XNCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    3/24/2026$13.00Overweight → Neutral
    Analyst
    11/24/2025Buy
    Truist
    10/29/2025$23.00Underweight → Overweight
    Barclays
    9/17/2025$6.00Underweight
    Barclays
    9/3/2025$12.00Buy → Neutral
    BofA Securities
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    2/15/24 4:02:46 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Biology Came First.

    Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is

    5/18/26 8:34:00 AM ET
    $ARGX
    $CGEM
    $HYFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Xencor Reports First Quarter 2026 Financial Results

    -- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start -- -- Plamotamab and XmAb657 autoimmune studies on-track for 2H26 progress update -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. "Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forwa

    5/6/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

    -- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™ format optimizes bispecifics for treatment of autoimmune diseases; first XenLock™ candidate XmAb412 first-in-human healthy participant study on track for 3Q26 start -- -- Management to host webcast tomorrow, Tuesday, May 5, at 8:00 a.m. EDT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long

    5/4/26 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Xencor downgraded by Analyst with a new price target

    Analyst downgraded Xencor from Overweight to Neutral and set a new price target of $13.00

    3/24/26 8:28:47 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Xencor

    Truist initiated coverage of Xencor with a rating of Buy

    11/24/25 8:31:08 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor upgraded by Barclays with a new price target

    Barclays upgraded Xencor from Underweight to Overweight and set a new price target of $23.00

    10/29/25 7:51:01 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    SEC Filings

    View All

    SEC Form 10-Q filed by Xencor Inc.

    10-Q - Xencor Inc (0001326732) (Filer)

    5/6/26 4:02:16 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Xencor Inc (0001326732) (Filer)

    5/6/26 4:01:13 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xencor Inc (0001326732) (Filer)

    5/5/26 8:41:27 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cornelissen Bart Jan

    4 - Xencor Inc (0001326732) (Issuer)

    4/13/26 4:01:46 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SR. VICE PRESIDENT & CSO Desjarlais John R sold $73,880 worth of shares (6,620 units at $11.16), decreasing direct ownership by 2% to 263,831 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    3/9/26 4:07:08 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, GENERAL COUNSEL Eckert Celia sold $55,952 worth of shares (5,011 units at $11.17), decreasing direct ownership by 6% to 76,918 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    3/9/26 4:06:45 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    View All

    Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen's capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein desig

    7/31/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Todd Simpson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

    3/13/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Bart Cornelissen as Chief Financial Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

    4/9/24 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 6:16:13 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 1:22:36 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/12/24 4:01:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Financials

    Live finance-specific insights

    View All

    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

    -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with a

    10/24/25 12:30:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at l

    10/21/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations